| LBCTR2022035012 | BIO-2021-0404 | Changes of Resting Metabolic Rate in University Athletes | Changes of Resting Metabolic Rate in University Athletes | Interventional | Pending | 14/03/2022 |
| LBCTR2022105089 | GBT021601-021 | A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease | A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease | Interventional | Pending | 07/07/2022 |
| LBCTR2020063513 | GBT440-038 | Open-Label Extension of Voxelotor | An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials | Interventional | Pending | 12/06/2020 |
| LBCTR2022125202 | DCR-PHXC-204 | A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis | A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis | Interventional | Pending | 21/11/2022 |
| LBCTR2023015204 | NCT05628389 | Phone Enabled Implementation of Cessation Support | Phone Enabled Implementation of Cessation Support | Interventional | Pending | 21/11/2022 |
| LBCTR2023015206 | R34MH121558 | Young adults as community mental health workers in humanitarian settings | Young adults as community mental health workers in humanitarian settings: A pilot test of the mechanisms of effect on their own well-being | Interventional | Pending | 24/11/2022 |
| LBCTR2023045220 | P-SP420-THAL-01 | An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent β-thalassemia | An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent β-thalassemia | Interventional | Pending | 13/12/2022 |
| LBCTR2022095118 | 4202-HEM-202 | Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease | A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease | Interventional | Pending | 08/09/2022 |
| LBCTR2023115324 | P3-IMU-838-RMS-01 (ENSURE-1) | A Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 (vidofludimus calcium) versus Placebo in Adults with Relapsing Multiple Sclerosis (RMS) | A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1) | Interventional | Pending | 30/03/2023 |
| LBCTR2023015151 | CLOU064C12301 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | Interventional | Pending | 14/10/2022 |